内分泌科医师之家

文献名称

短评:甲状旁腺功能减退症的新型治疗方法 [下载]
 
Mini-review: new therapeutic options in hypoparathyroidism
如无法下载,请点击此处

文献简介

出版社:Endocrine

作者:Natalie E. Cusano, Mishaela R. Rubin,James Sliney Jr., John P. Bilezikian

编号:10.1007/s12020-012-9618-y

关键字:Hypoparathyroidism;Parathyroid hormone;PTH(1-34);Teriparatide;PTH(1-84)

年份:2012点击量:744

文献摘要

Hypoparathyroidism is a disorder characterized by hypocalcemia and low or absent parathyroid hormone (PTH). While standard treatment of hypoparathyroidism consists of oral calcium and vitamin D supplementation, maintaining serum calcium levels can be a challenge, and concerns exist regarding hypercalciuria and ectopic calcifications that can be associated with such treatment. Hypoparathyroidism is the only classic endocrine deficiency disease for which the missing hormone, PTH, is not yet an approved treatment. This mini-review focuses on the use of PTH in the treatment of hypoparathyroidism. There are two available formulations of PTH: teriparatide [human PTH(1-34)] and the full-length molecule, PTH(1-84). Both PTH(1-34) and PTH(1-84) lower supplemental vitamin D requirements and increase markers of bone turnover. Densitometric and histomorphometric studies in some subjects treated with PTH(1-84) demonstrate improvement in abnormal bone-remodeling dynamics and return of bone metabolism toward normal euparathyroid levels. Further detailed examination of skeletal features following therapy with the different treatment regimens and data regarding the effect of PTH on quality of life measures are under active investigation.

甲状旁腺功能减退症是一种以低血钙、低或无甲状旁腺激素(PTH)为特征的疾病。虽然甲状旁腺功能减退症的标准治疗为口服钙剂和补充维生素D,但是维持血钙水平可能是一种挑战,并需关注与此疗法相关的高尿钙症和异位钙化的存在。甲状旁腺功能减退症是唯一缺失激素,且PTH治疗未经批准的典型内分泌缺乏症。本文侧重于描述使用PTH治疗甲状旁腺功能减退症。目前,PTH有两个可用的配方:特立帕肽[人类PTH(1-34)]和全长分子PTH(1-84)PTH(1-34)和PTH(1-84)均降低了补充维生素D的需求,但提高了骨转换指标。在一些使用PTH(1-84)治疗的受试者中,光密度和组织形态学研究表明,骨重建力学异常动态得到了改善,且骨代谢恢复到正常甲状腺激素水平。不同疗法的治疗后,需进一步地详细检查骨骼特征,此外,研究发现PTH影响生活质量的数据低于实际研究。

   

 

内分泌科医师之家